Systems of long-term (continuous) glucose monitoring are increasingly being used, one option is the flash glucose monitoring system (FGM). The use of the FGM system improves glycemic control compared to self-monitoring with glucose meter, but its availability is currently limited for most patients. The article suggests sources of financing of FGM systems based on legislative and regulatory legal regulation. Since the sensor that is necessary for the regular operation of the FGM system may be replaced by the patient at home the best way is to cover expenses from the outpatient healthcare budget. Accordingly, there are three possible sources of financing to ensure the use of the FGM system in outpatient settings: the system of compulsory medical insurance; budget funds of the subject of the Russian Federation — to provide medical products in accordance with the Decree of the Government of the Russian Federation No. 890; federal budget funds — to provide a set of social services in accordance with Federal Law No. 178-FZ. Medical organizations should also take into account the specifics of procurement and direct transfer of purchased systems to patients, taking into account the need for their use outside the medical organization. The FGM system does not have any features that distinguish it from any other medical devices in terms of the method of procurement. The regulation of procurement of FMG systems is quite transparent, but the design of their further treatment is not so obvious. According to the authors, the best option is to transfer a medical device to patients on the basis of a contract of gratuitous use. After the expiration of the period of gratuitous use, the patient must return the medical device for its further write-off by the budget organization according to the accounting rules.